Skip Navigation LinksHomeMedia CenterCorporate News

Corporate News

Minapharm Pharmaceuticals Announces the Successful Completion of its Phase 1 Clinical Trial in Europe for its Recombinant Teriparatide, Bonosome.

Minapharm Pharmaceuticals announces the successful completion of the phase 1 clinical trial in Germany evaluating its Teriparatide Biosimilar, Bonosome, a recombinant formulation of endogenous parathyroid hormone (PTH) injection indicated for mild to severe osteoporosis. This achievement marks the first African biosimilar to succeed in a European clinical trial, with an aim to enhance African self-sustainability and provide innovative, quality and affordable medicines to the region.

ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company

ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. The formation of MiGenTra accelerates ProBioGen's 2030 growth roadmap and showcases that further growth is not limited to the ongoing capacity increase but reveals one of several significant steps in the diversification of ProBioGen's business.

BioGaia Signs Exclusive Agreement in Egypt

BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The probiotic will be sold under the BioGaia brand. Launch is planned to Q4 2021.

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

Moscow/Cairo/Berlin, April 22, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world’s first registered vaccine against COVID-19, Sputnik V.

Minapharm Announces the First of its Kind Approval from the German Regulatory Authority BfArM to Conduct a Phase 1 Clinical Trial of a Biosimilar Developed in Egypt and the Region

Minapharm Pharmaceuticals S.A.E has announced today that the German regulatory authority BfArM (Federal Institute for Drugs and Medical Devices) approved a phase 1 clinical trial for its biosimilar teriparatide in Germany. The product has been submitted...

Minapharm Announces Appointment of Two New Board Members

Minapharm announced on July 27th 2020, the appointment of Dr. Shaheer Bardissi and Mr. Tarek Mounib as new members to the board of directors.

International Biotech Expert Dr. Lutz Hilbrich,
Now the CEO of ProBioGen AG

Minapharm pharmaceuticals, the leading biopharmaceutical company in Egypt, Africa and the Middle East, announced on June the 1st, the appointment of Dr. Lutz Hilbrich, an experienced biotech executive, as the new CEO of its Berlin-based subsidiary ProBioGen AG.

Latest Products Read More »

Newsletter Sign-up

Stay connected, subscribe to our newsletter
for news and updates.


Office Address

El-Bardissi St., 2T Takseem Asmaa Fahmy St., Heliopolis,
Cairo - Egypt.
Phone:(+202) 2414-3170/1/2/3/4/5
Fax:(+202) 2414-3179